Risk factors

Disc Medicine (IRON) risk factors

Item 1A of every Disc Medicine, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open IRON in Gloom →
Disc Medicine's chart, financials and news, free in your browser.Open IRON in Gloom →
  • FY2025 10-K risk factors
    90 risks15 new12 dropped25 reworded

    Disc Medicine faced a major setback when the FDA issued a Complete Response Letter (CRL) for bitopertin in EPP and XLP.

    Filed Feb 26, 2026
  • FY2024 10-K risk factors
    87 risks

    Disc Medicine faces substantial financial losses, having incurred a net loss of $109.4 million in 2024. The company has no approved products for commercial sale and relies entirely on clinical-stage hematologic programs. Operations depend heavily on third-party manufacturers, sole-source API suppliers, and collaborative partnerships like Mabwell and NIH.

    Filed Feb 27, 2025